HSBC on Monday double downgraded Eli Lilly and Co. (LLY) stock to ‘Reduce’ from ‘Buy’ and also lowered its price target to ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that day with the investment community and media ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...